<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Precis Oncol</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Precis Oncol</journal-id><journal-title-group><journal-title>NPJ Precision Oncology</journal-title></journal-title-group><issn pub-type="epub">2397-768X</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40394286</article-id><article-id pub-id-type="pmc">PMC12092662</article-id>
<article-id pub-id-type="publisher-id">921</article-id><article-id pub-id-type="doi">10.1038/s41698-025-00921-w</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Communication</subject></subj-group></article-categories><title-group><article-title>An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Arango-Argoty</surname><given-names>Gustavo</given-names></name><address><email>gustavo.arango@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Haghighi</surname><given-names>Marzieh</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sun</surname><given-names>Gerald J.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Choe</surname><given-names>Elizabeth Y.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Markovets</surname><given-names>Aleksandra</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Barrett</surname><given-names>J. Carl</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Lai</surname><given-names>Zhongwu</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Jacob</surname><given-names>Etai</given-names></name><address><email>etai.jacob@astrazeneca.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/043cec594</institution-id><institution-id institution-id-type="GRID">grid.418152.b</institution-id><institution-id institution-id-type="ISNI">0000 0004 0543 9493</institution-id><institution>Oncology R&#x00026;D, </institution><institution>AstraZeneca, </institution></institution-wrap>Waltham, MA USA </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>9</volume><elocation-id>147</elocation-id><history><date date-type="received"><day>5</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Circulating tumor DNA is a critical biomarker in cancer diagnostics, but its accurate interpretation requires careful consideration of clonal hematopoiesis (CH), which can contribute to variants in cell-free DNA and potentially obscure true tumor-derived signals. Accurate detection of somatic variants of CH origin in plasma samples remains challenging in the absence of matched white blood cells sequencing. Here we present an open-source machine learning framework (MetaCH) which classifies variants in cfDNA from plasma-only samples as CH or tumor origin, surpassing state-of-the-art classification rates.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Biomarkers</kwd><kwd>Cancer</kwd><kwd>Computational biology and bioinformatics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Main text</title><p id="Par2">Blood-based liquid biopsies are increasingly being explored for personalized cancer care, as circulating tumor DNA (ctDNA) can be detected in circulating cell-free DNA (cfDNA) of blood plasma liquid biopsies<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. The noninvasive, potentially longitudinal detection of tumor somatic variants from ctDNA could enable early diagnosis, improved biomarker detection and treatment selection, and disease monitoring<sup><xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR4">4</xref></sup>.</p><p id="Par3">However, accurate interpretation of ctDNA variants remains challenging, largely due to the presence of clonal hematopoiesis (CH) in cfDNA. CH refers to somatic variants in hematopoietic cells acquired over a lifetime, often affecting genes associated with aging, as well as those commonly altered in hematological malignancies and solid tumors, such as TP53<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. While high allele frequency variants can often be filtered out as likely germline or somatic non-tumor, recent evidence suggests that many low allele frequency variants arise from CH and not tumors<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. CH variants comprise of over 75% of cfDNA variants in individuals without cancer, and sometimes more than 50% of cfDNA variants in those with cancer<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Using cfDNA to diagnose, treat, or monitor cancer depends on accurately distinguishing CH variants from true tumor-derived mutations<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>.</p><p id="Par4">Studies characterizing the presence of variants in blood plasma cfDNA commonly utilize matched sequencing of a nucleated blood cell fraction (e.g. peripheral blood mononuclear cells or white blood cells) to determine variant origin (tumor or CH) in the absence of a tumor biopsy<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref></sup>. However, sequencing matched WBCs at the scale and depth required for clinical applications is often cost-prohibitive, time consuming, and impractical to implement<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR12">12</xref></sup>. Sequencing coverage must match cfDNA assay sensitivity, and WBCs require extra care due to their fragility compared to red blood cells. Matched WBC sequencing also has limitations&#x02014;CH is a dynamic process, where certain clones might exist in peripheral blood at levels below the detection threshold of standard sequencing yet still contribute detectable mutations to cfDNA. CH variants can be missed due to low variant allele frequency (VAF) in the WBC fraction, clonal heterogeneity, or sampling bias. Additionally, matched WBCs may not be available for retrospective studies or archived plasma samples. When only blood plasma sequencing is available, conventional analyses identify variants as CH by using reference databases of known variants associated with CH or hematological malignancies<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR13">13</xref></sup>, but many CH variants are specific to individuals or otherwise non-recurrent<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>, limiting the sensitivity of this approach. The VAF of key hematologic cancer driver genes has also been suggested as way to identify CH variants in cfDNA samples, but the exact relationship between VAF and variant origin remains unclear<sup><xref ref-type="bibr" rid="CR14">14</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. These challenges have driven interest in using machine learning (ML)-based methods to classify cfDNA variants<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref></sup>. While nascent, they show promise for further development of ML-based models for variant classification.</p><p id="Par5">Here, we propose MetaCH (a Metaclassifer for Clonal Hematopoiesis detection), an ML-based framework that accurately classifies CH variants in cfDNA samples in the absence of matched sequencing of WBCs. MetaCH processes variants through three stages and returns their corresponding CH-likelihood scores (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><title>The MetaCH framework.</title><p><bold>a</bold> Training the three stages of MetaCH: Stage 1: Mutational Enrichment Toolkit (METk) is trained on tumor and blood sequencing from a large, pan-cancer dataset to learn to generate variant (<inline-formula id="IEq1"><alternatives><tex-math id="d33e273">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{v}$$\end{document}</tex-math><mml:math id="d33e278"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq1.gif"/></alternatives></inline-formula>) and gene (<inline-formula id="IEq2"><alternatives><tex-math id="d33e286">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{g}$$\end{document}</tex-math><mml:math id="d33e291"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq2.gif"/></alternatives></inline-formula>) embeddings and functional prediction scores (<inline-formula id="IEq3"><alternatives><tex-math id="d33e299">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{f}$$\end{document}</tex-math><mml:math id="d33e304"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq3.gif"/></alternatives></inline-formula>). Stage 2: Base classifiers include a cfDNA-based classifier trained on a small cfDNA dataset with experimentally derived annotations (Razavi et al.) and two sequence-based classifiers trained on large datasets of pan-cancer tumor sequencing and blood sequencing with CH subtype annotations. The Sequence 1 classifier distinguishes CH-Oncogenic variants from others (tumor or CH-Non Oncogenic) and Sequence 2 distinguishes CH-Non Oncogenic variants from others (tumor or CH-Oncogenic). Stage 3: A meta classifier trained on Razavi et al. integrates base classifiers scores into a single variant origin prediction score (0: tumor; 1: CH). <bold>b</bold> Inference and validation: SNVs and indels from a cfDNA sample are processed through feature extraction and classification stages, yielding a single score predicting variant origin. Performance is evaluated using auROC and auPR curves on cfDNA datasets representing various cancer types, with ground truth derived from matched WBC sequencing.</p></caption><graphic xlink:href="41698_2025_921_Fig1_HTML" id="d33e316"/></fig></p><p id="Par6">In the first stage, variants, genes, and the impact of a variant on gene function are numerically represented via the Mutational Enrichment Toolkit (METk) (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). METk extracts three categories of features (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>, see Methods for details): variant embeddings (<inline-formula id="IEq4"><alternatives><tex-math id="d33e325">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{v}$$\end{document}</tex-math><mml:math id="d33e330"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq1.gif"/></alternatives></inline-formula>), gene embeddings (<inline-formula id="IEq5"><alternatives><tex-math id="d33e338">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{g}$$\end{document}</tex-math><mml:math id="d33e343"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq2.gif"/></alternatives></inline-formula>), and functional prediction scores (<inline-formula id="IEq6"><alternatives><tex-math id="d33e351">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{f}$$\end{document}</tex-math><mml:math id="d33e356"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq3.gif"/></alternatives></inline-formula>). Variant embeddings (<inline-formula id="IEq7"><alternatives><tex-math id="d33e365">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{v}$$\end{document}</tex-math><mml:math id="d33e370"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq1.gif"/></alternatives></inline-formula>) are learned through a self-supervised entity representation model inspired by StarSpace<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>, which maps variants into a shared embedding space based on their sequence context, associated gene, and cancer type. Gene embeddings (<inline-formula id="IEq8"><alternatives><tex-math id="d33e382">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{g}$$\end{document}</tex-math><mml:math id="d33e387"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq2.gif"/></alternatives></inline-formula>) capture patterns of genes with variants within individual patients, where each patient is represented as a bag of their genes with variants. This approach, inspired by word embeddings in natural language processing (NLP), learns numerical representations by leveraging co-occurrences of genes with variants within the same patient. The averaged embeddings of all genes with variants for a patient is denoted as <inline-formula id="IEq9"><alternatives><tex-math id="d33e395">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{{p}_{g}}$$\end{document}</tex-math><mml:math id="d33e400"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq9.gif"/></alternatives></inline-formula>, and the averaged embeddings of all variants for a patient is denoted as <inline-formula id="IEq10"><alternatives><tex-math id="d33e412">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{{p}_{v}}$$\end{document}</tex-math><mml:math id="d33e417"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq10.gif"/></alternatives></inline-formula>, providing a compact representation of the patient&#x02019;s mutation profile. Functional prediction scores (<inline-formula id="IEq11"><alternatives><tex-math id="d33e429">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{f}$$\end{document}</tex-math><mml:math id="d33e434"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq3.gif"/></alternatives></inline-formula>) quantify the impact of non-synonymous variants on gene function using publicly available databases and annotation tools (SnpEff, SnpSift) that integrate multiple prediction algorithms. These extracted features&#x02014;variant and gene embeddings, and functional prediction score&#x02014;provide information on the variant signature landscape, gene prevalence in cancer, and the functional effect of the variants to classifiers in the second stage.</p><p id="Par7">In the second stage, three base classifiers are trained using METk-generated features. First is a cfDNA-based classifier that learns to distinguish the origin of variants in the context of the cfDNA patient&#x02019;s samples (&#x0201c;cfDNA-Based Classifier&#x0201d;, Fig. <xref rid="Fig1" ref-type="fig">1a</xref>) and returns a CH-likelihood score (S<sub>cfDNA</sub>). It is trained on a smaller, publicly-available dataset from Razavi et al.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, in which variants are annotated using cfDNA and paired tumor- and WBC-matched sequencing. This cfDNA-based classifier employs several features: gene (<inline-formula id="IEq12"><alternatives><tex-math id="d33e453">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{g}$$\end{document}</tex-math><mml:math id="d33e458"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq2.gif"/></alternatives></inline-formula>), variant (<inline-formula id="IEq13"><alternatives><tex-math id="d33e466">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{v}$$\end{document}</tex-math><mml:math id="d33e471"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq1.gif"/></alternatives></inline-formula>), and patient-level embeddings (<inline-formula id="IEq14"><alternatives><tex-math id="d33e480">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{{Pg}}$$\end{document}</tex-math><mml:math id="d33e485"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Pg</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq14.gif"/></alternatives></inline-formula>, which represents the averaged embeddings of all genes within a patient and <inline-formula id="IEq15"><alternatives><tex-math id="d33e494">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{{Pv}}$$\end{document}</tex-math><mml:math id="d33e499"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Pv</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq15.gif"/></alternatives></inline-formula>, which represents the averaged embeddings of all variants within a patient), and functional variant scores (<inline-formula id="IEq16"><alternatives><tex-math id="d33e508">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{f}$$\end{document}</tex-math><mml:math id="d33e513"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq3.gif"/></alternatives></inline-formula>) from METk, as well as variant allele frequencies (<italic>VAF</italic>) and cancer type (<italic>Ct</italic>) for each patient.</p><p id="Par8">The second and third binary base classifiers are sequence-based classifiers which take advantage of large public datasets of tumor and blood-derived genomic sequencing to score the CH-likelihood of variants (&#x0201c;Sequence-Based Classifiers&#x0201d;, Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). Unlike cfDNA datasets with matched WBC sequencing, which are smaller than typical cancer genomic datasets and potentially limit model generalizability across cancer types and patient populations, we trained these additional second and third classifiers using two publicly available datasets for CH (blood-derived)<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> and somatic tumor (cancer-derived)<sup><xref ref-type="bibr" rid="CR20">20</xref></sup> variants from the Memorial Sloan Kettering Cancer Center. These datasets together comprise 77,068 tumor-derived and 9810 blood-derived variants spanning 59 cancer types. Following prior work<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, we removed duplicate variants and annotated CH variants into two subgroups based on their putative role in cancer pathogenesis or recurrence in myeloid neoplasms. This resulted in a final three-class dataset of putative cancer driver (CH-Oncogenic) variants, variants not-related to cancer pathogenesis (CH-Non-Oncogenic), and tumor variants. The Sequence 1 classifier predicts CH-Oncogenic from other variants (tumor or CH-Non-Oncogenic, S<sub>Sequence 1</sub>) and Sequence 2 predicts CH-Non-Oncogenic from others (tumor or CH-Oncogenic, S<sub>Sequence 2</sub>).</p><p id="Par9">Finally, the last stage (&#x0201c;Meta-Classifier&#x0201d;, Fig. <xref rid="Fig1" ref-type="fig">1a</xref>) is a meta-classifier trained by applying each of the base classifiers to the cfDNA dataset from Razavi et al.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> to generate scores (S<sub>cfDNA</sub>, S<sub>Sequence 1</sub>, S<sub>Sequence 2</sub>) representing the probability of each variant having blood (CH) origin. It uses logistic regression to optimally combine the scores from the base classifiers as meta-features into one, final S<sub>Meta</sub> score. This score represents the probability that a variant originates from CH (1) or tumor (0).</p><p id="Par10">In the inference mode (Fig. <xref rid="Fig1" ref-type="fig">1b</xref>), given a pool of cfDNA variants, the three stages of the MetaCH framework process the data and predicts a single CH likelihood score for each variant.</p><p id="Par11">We evaluated the performance of the full framework and the standalone performance of each base classifier using cross-validation of the Razavi et al.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> training samples and reported the results as both area under the Precision-Recall (auPR) and the Receiver Operating Characteristic (auROC) curves in Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>. The cfDNA-based classifier achieved comparable auPR and auROC as the complete MetaCH framework, despite being trained on the smallest dataset. This underscores the importance of training on cfDNA data with ground truth from matched sequencing data. The complete MetaCH framework showed noticeable advantages when applied to four independent external cfDNA validation datasets with matched WBC sequencing (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>)<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref></sup>. In the Chabon et al. dataset, the cfDNA-based classifier exhibited the highest auPR of the subclassifiers, while in Leal et al., Chin et al., and Zhang et al., it was a sequence-based classifier. However, the MetaCH framework consistently delivered the highest auPR (or one comparable to the highest) across these four datasets compared to the subclassifiers. MetaCH also outperformed existing machine learning approaches<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR16">16</xref></sup>. Across all external validation datasets, MetaCH demonstrated superior performance in predicting variant origin (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>, Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><title>Performance evaluation of MetaCH on external validation datasets.</title><p><bold>a</bold> Performance comparison of our proposed model (MetaCH) versus the machine-learning based baseline models for CH classification reveals that the proposed model consistently outperforms the baseline models in identifying the origin of variants across four independent validation datasets according to the area under the precision-recall and ROC curves shown in the first and second rows respectively (denoted by auPR and auROC). <bold>b</bold> Per dataset PR curves (first row) with average ROC curves (second row) comparing MetaCH&#x02019;s performance with and without canonical CH genes across external validation datasets. MetaCH achieves an auROC of 0.79 when canonical CH genes (DNMT3A, TET2, and ASXL1) are included and an auROC of 0.73 when these genes are excluded from the external validation datasets. ROC curves illustrate overall model performance on the external validation datasets, with shaded areas representing the standard deviation across datasets. <bold>c</bold> PR (first row) and ROC (second row) curves comparing MetaCH&#x02019;s performance on subsets of the Chabon et al.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> and Zhang et al.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> datasets containing genes within and outside the Razavi et al.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> training panel. <bold>d</bold> Permutation feature importance by feature group, measured as mean drop in auPR. Feature importance is assessed across training and external validation datasets, with each bar representing the mean drop in auPR when permuting a specific feature group. In the training data, gene embeddings (<inline-formula id="IEq17"><alternatives><tex-math id="d33e639">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$E_g$$\end{document}</tex-math><mml:math id="d33e644"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq17.gif"/></alternatives></inline-formula>) and VAF emerge as the most influential features. In external validation data, variant embeddings (<inline-formula id="IEq18"><alternatives><tex-math id="d33e652">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$E_v$$\end{document}</tex-math><mml:math id="d33e657"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq18.gif"/></alternatives></inline-formula>) show the highest importance, though with substantial variability across datasets. Gene embeddings (<inline-formula id="IEq19"><alternatives><tex-math id="d33e665">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$E_g$$\end{document}</tex-math><mml:math id="d33e670"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq17.gif"/></alternatives></inline-formula>) exhibit lower variability, indicating their consistent importance across both training and validation datasets. Error bars represent standard deviation across permutation repetitions (<italic>n</italic>&#x02009;=&#x02009;30) for the training dataset and standard deviation across datasets for the external validation plot.</p></caption><graphic xlink:href="41698_2025_921_Fig2_HTML" id="d33e682"/></fig></p><p id="Par12">Interestingly, the classifier designed to differentiate CH-Oncogenic variants from others exhibited higher auROC and auPR compared to the CH-Non-Oncogenic classifier (Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>). This suggests that CH-Oncogenic variants are easier to distinguish from tumor variants than CH-Non-Oncogenic variants. This observation could be explained by the distinct genetic signatures associated with different variant types. CH-Oncogenic variants, while precancerous, exhibit variant fingerprints strongly correlated with myeloid lineage and aging, as noted in Bolton et al.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, whose classification we adopted for our annotations. In contrast, tumor variant fingerprints are influenced by a wider array of factors, including environmental exposures (e.g. tobacco use, UV radiation) and tumor-specific mutational processes (e.g. APOBEC activity)<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, leading to greater variability in their variant signatures. CH-Non-Oncogenic variants, being minimally myeloid-derived, may be associated with a broader spectrum of variant signatures, including ones overlapping with tumor, making them harder to classify<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. This pattern suggests that our model&#x02019;s ability to capture differences in variant landscapes, in both the sequence-based classifiers and embeddings learned in stage 1, can help indicate the origin of the variants<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>.</p><p id="Par13">To assess our model&#x02019;s dependence on the most prevalent CH-associated genes and its ability to generalize to less common CH variants, we evaluated its performance on an external validation set where all variants in the most prevalent genes in clonal hematopoietic cells (<italic>DNMT3A</italic>, <italic>TET2</italic>, and <italic>ASXL1</italic>)<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> were removed. MetaCH&#x02019;s performance dropped by approximately 6% (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>), indicating that while these genes contribute to classification, they do not disproportionately influence outcomes, and the model still retains predictive capability based on other features.</p><p id="Par14">To assess potential bias towards variants in genes within the training set panel, we evaluated model performance on subsets of the Chabon et al. and Zhang et al. containing genes within and outside the training panel. Results reveal a bias towards training set panel genes (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>) and highlight the need for more panel-diverse annotated cfDNA samples in future training sets. Despite this bias, the model maintained predictive power beyond random classification, even for out-of-panel genes.</p><p id="Par15">Finally, we evaluated the importance of each feature category in the MetaCH model using a permutation importance test (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>). While VAF emerged as the most influential feature in the training data, its importance varied across validation datasets and was, on average, less than that of METk-extracted features. This highlights the contribution and generalizability of these embeddings, which learn from a large, complementary data source and add important information beyond what can be learned from matched cfDNA sequencing alone. Overall, gene embeddings (<inline-formula id="IEq20"><alternatives><tex-math id="d33e739">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{g}$$\end{document}</tex-math><mml:math id="d33e744"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq2.gif"/></alternatives></inline-formula>) were the most informative category for determining variant origin across both training and external validation datasets. Variant embeddings (<inline-formula id="IEq21"><alternatives><tex-math id="d33e752">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{v}$$\end{document}</tex-math><mml:math id="d33e757"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq1.gif"/></alternatives></inline-formula>) and functional prediction scores (<inline-formula id="IEq22"><alternatives><tex-math id="d33e765">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{f}$$\end{document}</tex-math><mml:math id="d33e770"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq3.gif"/></alternatives></inline-formula>) showed considerable variability in importance across various external validation datasets.</p><p id="Par16">MetaCH performance varied across the datasets, likely due to differences in variant-calling and processing methods, sequencing depth and coverage, sample preparation and sequencing protocols, as well as patient populations. As a result, the model may learn subtle patterns specific to these factors that do not perfectly generalize to other datasets. Nevertheless, MetaCH&#x02019;s performance on independent validation datasets remained within 10% of the cross-validation scores. Its strong performance on the Leal et al. dataset (auPR/auROC 0.89/0.84 compared to 0.8/0.73 for the Fairchild et al.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> model and 0.54/0.48 for the SSGAN<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> model) is especially reassuring, as this data comes from gastric cancer patients&#x02014;a cancer type not covered in the Razavi et al.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> matched cfDNA training dataset. Additionally, MetaCH&#x02019;s consistent superior performance over existing ML models across all the external validation datasets highlights the advantage of strategies that leverage diverse sources of available information into a single learning framework.</p><p id="Par17">The variation in performance might not only reflect limitations of the model but could also result from inconsistencies in ground truth labeling in datasets. Razavi et al.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>, used to train the cfDNA-based classifier, had the highest depth of coverage among the cfDNA WBC-matched datasets. Lower depth in WBC sequencing could lead to missed variants, potentially misclassifying some CH variants as tumor derived. MetaCH demonstrated significantly poorer performance on the Zhang et al. dataset, which had a marked difference in sequencing depth between plasma (1000&#x000d7;) and WBC samples (400&#x000d7;), unlike other studies, which used higher and more consistent sequencing depths. This disparity likely contributed to misclassification, especially for low VAF variants, resulting in a high false-positive rate (also observed by Fairchild et al.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>). While MetaCH might identify CH variants missed in the ground truth annotations of external datasets, the extent this effect is unclear. Further investigation using datasets with replicate matched controls and varying sequencing depths would help quantify this phenomenon.</p><p id="Par18">Despite its promising results, MetaCH has limitations. Translating the model for clinical use requires establishing a relationship between reported metrics such as auROC and auPR with clinically meaningful outcomes. Ground truth experiments to correlate, for example, auPR with minimal residual disease false positive rates, are necessary for applying ML tools like MetaCH to the clinic. Future iterations of MetaCH could also incorporate patient-level features associated with CH, such as age<sup><xref ref-type="bibr" rid="CR27">27</xref></sup> and prior chemotherapy exposure<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>, as well as cfDNA-specific features such as fragmentomics<sup><xref ref-type="bibr" rid="CR28">28</xref></sup> or methylation<sup><xref ref-type="bibr" rid="CR29">29</xref></sup> to further improve the classification accuracy and clinical utility. Additionally, incorporating more panel-diverse annotated cfDNA samples in future training sets may improve the generalizability of this approach, as targeted sequencing, with its inherent genomic limitations, remains the primary approach in clinical cfDNA assays due to its high sensitivity required for translational research.</p><p id="Par19">MetaCH represents a significant step towards more accurate CH variant identification in cfDNA samples. As we continue to refine and validate this approach, it has the potential to improve the accuracy of liquid biopsy-based cancer diagnostics and monitoring, ultimately contributing to more personalized and effective cancer care.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Datasets</title><p id="Par20">This study utilizes multiple datasets for training and evaluating the classification of cfDNA variants (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). These datasets include publicly available blood and tumor sequencing data, as well as cfDNA samples collected from patients. The publicly available datasets were obtained from The Cancer Genome Atlas (TCGA), cBioPortal, and previously published studies. Each dataset varies in sequencing depth, variant composition, and patient cohort characteristics, providing a comprehensive foundation for model development and validation.</p><p id="Par21">The details of each dataset are provided in the corresponding sections describing the framework components that utilize them.</p></sec><sec id="Sec4"><title>Mutational Enrichment Toolkit (METk): extracting general-purpose gene and variant embeddings</title><p id="Par22">To generate embeddings for individual variants, genes, and cancer patients, we developed and applied the variants Enrichment Toolkit (METk), a framework that combines self-supervised natural language processing techniques with large-scale genomic datasets to create comprehensive, context-aware representations of genetic variants. METk is a Python API that takes in a table with pre-processed variants annotation format (MAF) files annotated with cancer type and returns variant embeddings (<inline-formula id="IEq23"><alternatives><tex-math id="d33e837">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{v}$$\end{document}</tex-math><mml:math id="d33e842"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq1.gif"/></alternatives></inline-formula>), gene embeddings (<inline-formula id="IEq24"><alternatives><tex-math id="d33e850">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{g}$$\end{document}</tex-math><mml:math id="d33e855"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq2.gif"/></alternatives></inline-formula>), patient-level variant embeddings (<inline-formula id="IEq25"><alternatives><tex-math id="d33e863">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{{p}_{v}}$$\end{document}</tex-math><mml:math id="d33e868"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq10.gif"/></alternatives></inline-formula>), patient-level gene embeddings (<inline-formula id="IEq26"><alternatives><tex-math id="d33e880">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{{p}_{g}}$$\end{document}</tex-math><mml:math id="d33e885"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq9.gif"/></alternatives></inline-formula>), and functional prediction scores of each variant (<inline-formula id="IEq27"><alternatives><tex-math id="d33e897">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{f}$$\end{document}</tex-math><mml:math id="d33e902"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq3.gif"/></alternatives></inline-formula>).</p><p id="Par23">Mutational somatic signatures serve as a fingerprint for characterizing the underlying biology of cancer. Tumor somatic variants tend to leave a strong signature in the cancer cells that can indicate the multiple biological mechanisms present in the tumor (e.g., Aging, Tobacco smoking, APOBEC activity). In cfDNA samples, the enrichment of these signatures may indicate the origin of the variants<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR24">24</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>. As the prevalence of clonal hematopoietic variants is associated with the aging process, scoring the aging signature for individual variants can help to identify the origin of blood-derived variants. In the same context, identifying the tumor mutational signatures may help to identify the variants that are originated from the tumor. Therefore, identifying the mutational landscape from individual variants can contribute with the identification of its origin.</p><p id="Par24">Prior research has demonstrated that larger variant sequence contexts can enrich information content of genomic data<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>, yet translating these contexts into a compact and meaningful set of numeric features remains an ongoing area of study. More recently, researchers have leveraged advances in natural language processing (NLP) to create a shared embedding space for patients and variants based on the larger-scale sequence context of variants<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. Besides leveraging larger sequence context, studies have also explored generating gene embeddings based on co-occurrence patterns using NLP-inspired techniques<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR33">33</xref></sup>.</p><p id="Par25">Inspired by these ideas, we developed the METk framework, which generates embeddings for genes and variants (Supplementary Fig. <xref rid="MOESM1" ref-type="media">2</xref>), in addition to scores that characterize variant impact on gene function, as described below.</p></sec><sec id="Sec5"><title>Variant embeddings</title><p id="Par26">Variant embeddings are low-dimensional numerical representations (|<italic>E</italic><sub><italic>v</italic></sub><italic>| = d</italic>, i.e. a <italic>d</italic>&#x02212;dimensional space) of genetic variants, capturing underlying patterns in variant data. These embeddings facilitate various downstream analyses, including variant classification, disease association studies, and variant effect prediction. To generate these embeddings, we leveraged the StarSpace<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> model, a self-supervised learning framework originally developed for learning entity representations from structured data. This approach derives variant embeddings that encode biological context and co-occurrence patterns within patient variant profiles.</p><p id="Par27">In this framework, each patient is represented as a set of genetic variants, analogous to an entity with multiple associated features. Therefore, the patient entity is modeled as a bag of all its variants, while the variant entity is described by a set of tokens, including the specific variant, its sequence context, associated gene, and cancer type (if available) (Fig. <xref rid="Fig1" ref-type="fig">1a</xref>). The model is trained using a contrastive learning approach, maximizing the similarity between co-occurring variants within the same patient while distinguishing them from randomly sampled negative variants.</p><p id="Par28">To incorporate variant sequence context, we extract 2, 3, 4, and 5-mers from a 20-base pair window (10&#x02009;bp upstream and 10&#x02009;bp downstream from the variant&#x02019;s location). During inference, cancer type is excluded as a feature to ensure the learned variant embeddings generalize across datasets.</p><p id="Par29">For training, we utilized the pan-cancer TCGA dataset along with a subset of pan-cancer studies from cBioPortal (<ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov">https://portal.gdc.cancer.gov</ext-link>, &#x0201c;msk_impact_2017&#x0201d;, &#x0201c;msk_ch_2020&#x0201d;, &#x0201c;tmb_mskcc_2018&#x0201d;, &#x0201c;pan_origimed_2020&#x0201d;, &#x0201c;pancan_pcawg_2020&#x0201d;, &#x0201c;msk_met_2021&#x0201d; downloaded from cBioPortal.org). This large-scale dataset enables the model to capture genomic, molecular, and clinical patterns, supporting applications such as variant effect prediction, cancer subtype classification, and patient stratification.</p></sec><sec id="Sec6"><title>Gene embeddings</title><p id="Par30">Gene embeddings are low-dimensional vector representations that capture the functional relationships and co-variant patterns of genes. By mapping genes into a continuous embedding space, these representations encode biological relevance in a way that facilitates downstream tasks such as variant effect prediction, patient stratification, and pathway analysis. Inspired by the Continuous Bag-of-Words (CBOW) model from natural language processing (NLP), the Continuous Bag-of-Mutated Genes (CBMG) Model is a self-supervised approach for learning gene embeddings based on their co-occurrence in patient variant profiles. We used the pan-cancer mutational dataset from TCGA, where each entry is represented by a list of mutated genes, to train the model. In this framework, each patient is represented as a bag of mutated genes, analogous to a sentence composed of words. During training, a gene is randomly selected as the target, while the remaining mutated genes in the patient&#x02019;s sample serve as the context. The model optimizes an objective function to predict the target gene based on its co-occurring genes, learning embeddings that capture underlying biological relationships, co-patterns, and functional similarity. The resulting gene embeddings can be utilized for various biomedical applications, including mutation-driven disease characterization and network-based gene function prediction.</p></sec><sec id="Sec7"><title>Patient-level gene and variant embeddings</title><p id="Par31">For both gene and variant embeddings, patient-level embeddings are computed as the average of all gene or variant embeddings within each patient. Specifically, the patient-level variant embedding (<inline-formula id="IEq28"><alternatives><tex-math id="d33e984">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{{p}_{v}}$$\end{document}</tex-math><mml:math id="d33e989"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq10.gif"/></alternatives></inline-formula>) and patient-level gene embedding (<inline-formula id="IEq29"><alternatives><tex-math id="d33e1001">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{{p}_{g}}$$\end{document}</tex-math><mml:math id="d33e1006"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq9.gif"/></alternatives></inline-formula>) are obtained by averaging the embeddings of all variants or genes associated with a given patient, as illustrated in the figures for each embedding approach.</p></sec><sec id="Sec8"><title>Functional prediction scores</title><p id="Par32">Functional prediction scores (<inline-formula id="IEq30"><alternatives><tex-math id="d33e1022">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{f}$$\end{document}</tex-math><mml:math id="d33e1027"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq3.gif"/></alternatives></inline-formula>) are extracted to provide additional information to the variant and gene embeddings. These scores are specifically obtained for non-synonymous variants, as they quantify the potential impact of variants on gene function and their likelihood of conferring a selective advantage in malignancies. We incorporated SnpEff<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>, a database that compiles prediction scores from multiple algorithms assessing the potential of amino acid substitutions on protein function, and SnpSift<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>, a tool that allows annotation and filtering of variants based on the SnpEff database. The resulting functional prediction scores (<inline-formula id="IEq31"><alternatives><tex-math id="d33e1043">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{f}$$\end{document}</tex-math><mml:math id="d33e1048"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq3.gif"/></alternatives></inline-formula>) offer an estimate of a variant&#x02019;s potential contribution to cancer development.</p></sec><sec id="Sec9"><title>METk utilization</title><p id="Par33">All these features are available through the Mutation Enrichment Toolkit (METk), a Python API designed to automatically extract the described embeddings. The METk framework supports the processing of both single nucleotide variants (SNVs) and insertions/deletions (INDELs), enabling a comprehensive analysis of mutation-derived embeddings. The final embedding dimensions used in MetaCH were <inline-formula id="IEq32"><alternatives><tex-math id="d33e1060">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$|{E}_{v}|=128$$\end{document}</tex-math><mml:math id="d33e1065"><mml:mrow><mml:mi>|</mml:mi><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mi>|</mml:mi><mml:mo>=</mml:mo><mml:mn>128</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq32.gif"/></alternatives></inline-formula>, <inline-formula id="IEq33"><alternatives><tex-math id="d33e1078">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{|E}}_{g}|=8$$\end{document}</tex-math><mml:math id="d33e1083"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">|E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub><mml:mi>|</mml:mi><mml:mo>=</mml:mo><mml:mn>8</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq33.gif"/></alternatives></inline-formula> and <inline-formula id="IEq34"><alternatives><tex-math id="d33e1096">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{|E}}_{f}|=37$$\end{document}</tex-math><mml:math id="d33e1101"><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">|E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub><mml:mi>|</mml:mi><mml:mo>=</mml:mo><mml:mn>37</mml:mn></mml:mrow></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq34.gif"/></alternatives></inline-formula>.</p></sec><sec id="Sec10"><title>cfDNA-based classifier</title><p id="Par34">The cfDNA-based classifier is a binary classifier which classifies each variant in a patient&#x02019;s cfDNA sample as originating from CH or tumor (&#x0201c;cfDNA-Based Classifier,&#x0201d; Fig. <xref rid="Fig1" ref-type="fig">1b</xref>). This classifier was trained and validated using the cfDNA Razavi et al.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup> dataset which includes annotations of variants as either tumor-derived or CH. These annotations were determined through matched plasma, tumor biopsy, and WBC sequencing from 124 patients with non-small cell lung, breast, or prostate cancer, where 53.2% of the patients harbored variants indicative of CH. Plasma and WBC were sequenced using a panel of 508 genes with &#x0003e;60,000x raw depth coverage. The study provides detailed annotation of cfDNA variants, including VAF, cancer type, and identifying their origin as blood or tumor. Variants of unknown significance that did not match either blood or tumor were excluded from our analysis. Specifically, 436 tumor somatic variants and 914 blood CH derived variants were used for training this classifier.</p><p id="Par35">This classifier is optimized to distinguish between clonal hematopoiesis (CH) and tumor-derived variants in circulating cell-free DNA and provides a probability score (<inline-formula id="IEq35"><alternatives><tex-math id="d33e1127">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${S}_{{cfDNA}}$$\end{document}</tex-math><mml:math id="d33e1132"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">cfDNA</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq35.gif"/></alternatives></inline-formula>) which represents the likelihood of a given variant being classified as CH rather than tumor-derived. This score is subsequently integrated into the final stage of framework (the meta classifier), as shown in &#x0201c;Meta-Classifier,&#x0201d; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>. Features used to train this classifier were variant and gene embeddings (<inline-formula id="IEq36"><alternatives><tex-math id="d33e1144">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{v}$$\end{document}</tex-math><mml:math id="d33e1149"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq1.gif"/></alternatives></inline-formula>, <inline-formula id="IEq37"><alternatives><tex-math id="d33e1157">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{g}$$\end{document}</tex-math><mml:math id="d33e1162"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq2.gif"/></alternatives></inline-formula>), patient-level embeddings (<inline-formula id="IEq38"><alternatives><tex-math id="d33e1170">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{{Pv}}$$\end{document}</tex-math><mml:math id="d33e1175"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Pv</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq15.gif"/></alternatives></inline-formula>, <inline-formula id="IEq39"><alternatives><tex-math id="d33e1185">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{{p}_{g}}$$\end{document}</tex-math><mml:math id="d33e1190"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq9.gif"/></alternatives></inline-formula>), and functional prediction scores (<inline-formula id="IEq40"><alternatives><tex-math id="d33e1202">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{f}$$\end{document}</tex-math><mml:math id="d33e1207"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq3.gif"/></alternatives></inline-formula>) derived by METk, variant per patient-level (<italic>VAF</italic>), and cancer type (<italic>Ct</italic>).</p></sec><sec id="Sec11"><title>Sequence-based classifiers</title><p id="Par36">Unlike the cfDNA-based classifier, the sequence-based classifiers were not trained on matched cfDNA data, but rather on data derived from blood and tumor samples. First, 77,068 tumor-derived variants were extracted from a study which sequenced tumors from 10,000 patients with 59 types of cancer (available at <ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/">https://www.cbioportal.org/</ext-link> &#x0201c;msk_impact_2017&#x0201d;). Second, 9810 blood-derived variants were extracted from a study which sequenced blood from 6650 patients (available at <ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/">https://www.cbioportal.org/</ext-link> &#x0201c;msk_ch_2020&#x0201d;). We annotated variants in our training data according to the CH subtype annotation described in Bolton et al.<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>. Their approach labeled variants based on their putative role in cancer pathogenesis using OncoKB<sup><xref ref-type="bibr" rid="CR36">36</xref></sup> and their recurrence in a dataset of myeloid neoplasms<sup><xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref></sup>. Specifically, 5800 variants were labeled as Clonal Hematopoietic putative cancer drivers (termed &#x0201c;CH-Oncogenic&#x0201d; in our study, equivalent to &#x0201c;CH-PD&#x0201d; for CH-putative driver in Bolton et al.). A total of 4010 blood variants were labeled as non-related to cancer pathogenesis (termed &#x0201c;CH-Non Oncogenic&#x0201d; in our study, an unnamed group in Bolton et al.).</p><p id="Par37">After removing duplicate variants within each dataset independently, a total of 57,210 tumor variants, 2967 CH-Non Oncogenic, and 3778 CH-Oncogenic variants were used to train FlaML (Fast and Lightweight AutoML, a Python library that automates model selection and efficiently tunes hyperparameters<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>) to select and optimize two binary classifiers: The Sequence 1 classifier predicts CH-Oncogenic variants versus others (tumor or CH-Non-Oncogenic) and was trained using the CH-Oncogenic variants as the primary class while the CH-Non-Oncogenic and tumor variants were used as the secondary class. The Sequence 2 classifier predicts CH-Non-Oncogenic variants versus others (tumor or CH-Oncogenic) and was trained using the CH-Non-Oncogenic variants as the primary class while the CH-Oncogenic and tumor variants were used as the secondary class. The rationale for having two specialized binary classifiers within the space of these three categories is that CH-Oncogenic and CH-Non-Oncogenic variants exhibit distinct biological roles and decision boundaries. Training separate classifiers allows each model to optimize feature selection specific to its classification task, potentially improving prediction accuracy and interpretability.</p><p id="Par38">Each binary classifier is optimized to learn features that distinguish the origins of CH subtypes, providing scores as probabilities of each variant belonging to either CH-Oncogenic (<inline-formula id="IEq41"><alternatives><tex-math id="d33e1256">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${S}_{{Sequence}1}$$\end{document}</tex-math><mml:math id="d33e1261"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Sequence</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq41.gif"/></alternatives></inline-formula>) or CH-Non-Oncogenic (<inline-formula id="IEq42"><alternatives><tex-math id="d33e1271">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${S}_{{Sequence}2}$$\end{document}</tex-math><mml:math id="d33e1276"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Sequence</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq42.gif"/></alternatives></inline-formula>).These scores are subsequently processed by the meta-classifier, as illustrated in &#x0201c;Meta-Classifier,&#x0201d; Fig. <xref rid="Fig1" ref-type="fig">1a</xref>.</p><p id="Par39">The set of features used to train the sequence-based classifiers are the variant embeddings (<inline-formula id="IEq43"><alternatives><tex-math id="d33e1291">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{v}$$\end{document}</tex-math><mml:math id="d33e1296"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq1.gif"/></alternatives></inline-formula>), the gene level embeddings (<inline-formula id="IEq44"><alternatives><tex-math id="d33e1304">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{g}$$\end{document}</tex-math><mml:math id="d33e1309"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>g</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq2.gif"/></alternatives></inline-formula>), the functional prediction scores (<inline-formula id="IEq45"><alternatives><tex-math id="d33e1317">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${E}_{f}$$\end{document}</tex-math><mml:math id="d33e1322"><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mrow><mml:mi>f</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq3.gif"/></alternatives></inline-formula>) and the cancer type (<italic>Ct</italic>).</p></sec><sec id="Sec12"><title>Meta classifier</title><p id="Par40">To integrate the complementary information from the cfDNA-based and sequence-based classifiers, we developed a metaclassifier that takes as input the probability scores from each of the three base classifiers for each variant (meta-features). The Meta-Classifier learns a function to distribute weights across various sources of evidence <inline-formula id="IEq46"><alternatives><tex-math id="d33e1337">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${S}_{{Meta}}=f\left(\alpha {S}_{{cfDNA}}+\beta {S}_{{Sequence}1}+\gamma {S}_{{Sequence}2}\right)$$\end{document}</tex-math><mml:math id="d33e1342"><mml:mrow><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Meta</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>f</mml:mi><mml:mrow><mml:mfenced close=")" open="("><mml:mrow><mml:mi>&#x003b1;</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">cfDNA</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b2;</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Sequence</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>&#x003b3;</mml:mi><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Sequence</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq46.gif"/></alternatives></inline-formula>. We used a logistic regression classifier to learn this function. To avoid overfitting, we used the same training and validation dataset splits employed in training the cfDNA-based classifier, as both classifiers were trained on the same data samples but with different features. The meta classifier predicts a final probability score (<inline-formula id="IEq47"><alternatives><tex-math id="d33e1382">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${S}_{{Meta}}$$\end{document}</tex-math><mml:math id="d33e1387"><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">Meta</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="41698_2025_921_Article_IEq47.gif"/></alternatives></inline-formula>), which serves as the ultimate classification output, determining the likelihood of a variant being classified as CH.</p></sec><sec id="Sec13"><title>Model selection and performance evaluation</title><p id="Par41">Each evidence-generating classifier was trained using FlaML (Fast and Lightweight AutoML), a Python library that automates model selection and efficiently tunes hyperparameters<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. FlaML applies a range of classification algorithms (such as random forests, gradient boosting, and neural networks) to a task, systematically varying their hyperparameters and selecting the best-performing model based on cross-validated performance metrics.</p><p id="Par42">We conducted stratified 5-fold cross-validation to evaluate the performance of each classifier in the training phase. Both the area under the Receiver Operating Characteristic curve (auROC) and the area under the Precision-Recall curve (auPR) were used and reported as evaluation metrics. Due to the class imbalance in most datasets, we primarily focused on auPR for result interpretation, while auROC is reported where relevant.</p><p id="Par43">To provide a comprehensive evaluation on various external validation datasets, we have included both ROC and PR curves, which offer additional insights beyond their respective area-under-the-curve (AUC) values. ROC curves illustrate the trade-off between sensitivity and specificity, making them useful for understanding model performance across all classification thresholds. Meanwhile, PR curves highlight precision-recall dynamics, which are particularly relevant in settings with class imbalance, as they emphasize a model&#x02019;s ability to identify positive instances without being misled by the abundance of negative samples. Together, these visualizations provide a detailed characterization of classifier performance, complementing the AUC metrics.</p></sec><sec id="Sec14"><title>Benchmarking datasets and methods</title><p id="Par44">To assess the generalizability of MetaCH, we tested its performance on independent, publicly available cfDNA datasets representing a range of sequencing technologies, depths of coverage, post-sequencing analysis pipelines, cancer types, and clinical profiles<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref></sup>. All datasets included in our benchmarking studies utilized matched WBC sequencing such that all variants were annotated as either CH or tumor-derived by the studies<sup><xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref></sup>.</p><p id="Par45">Chin et al.<sup><xref ref-type="bibr" rid="CR22">22</xref></sup> conducted ultradeep sequencing on cfDNA and WBCs from 100 breast cancer patients, equally divided between early-stage and advanced-stage disease. They used an amplicon-based panel with unique molecular tagging (UMT) to perform targeted-gene sequencing, covering 1021 cancer-related genes and achieving an average sequencing depth of approximately 4000x unique reads. Variant calling was performed using the Ion Reporter software. The study detected ctDNA in 43% of early-stage and 86% of advanced-stage patients, identifying 72 variants in 19 genes and finding a strong correlation of CH variants with age.</p><p id="Par46">Chabon et al.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> analyzed 85 patients with stage I-III non-small cell lung cancer (NSCLC) using a personalized deep sequencing method. They matched tumor tissue, pretreatment plasma cfDNA, and leukocyte DNA for each patient, sequenced at a depth of 4000&#x02013;5000&#x000d7;, and identified 909 variants from 255 genes. They used CAPP-seq with an error suppression model for variant calling and analysis. Similar to the Razavi et al. study, the majority of cfDNA variants in this cohort reflect CH and are non-recurrent. For our validation, we selected only the NSCLC variants labeled as absent (tumor) or present (blood) in matched leukocytes.</p><p id="Par47">Leal et al.<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> performed matched, targeted sequencing of cfDNA and matched WBCs of 50 gastric cancer patients (stages IB-IVA), both to a depth of 30,000&#x000d7;. They used VariantDx for variant calling and identified 224 variants in 28 genes.</p><p id="Par48">Zhang et al.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> sequenced matched plasma and WBC samples from over 10,000 Chinese patients with various cancer types (stages I-IV) using parallel sequencing. They sequenced plasma at 1000&#x000d7; coverage and WBC at 400&#x000d7; coverage, using MutTect2 and quality filters for mutation calling and processing. The study used a targeted sequencing panel to detect ctDNA mutations. The mutation profiles varied across different cancer types, with certain mutations being more prevalent in specific cancers.</p><p id="Par49">We compared the performance of MetaCH of these datasets with two existing machine learning approaches: Fairchild et al.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>, which uses classical ML approaches on variant- and population-level features (including VAF, CH gene occurrence, and variant frequencies) in public databases and is trained on the Razavi et al. cfDNA with matched WBC dataset (similar to our cfDNA-based classifier), and SSGAN<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>, which uses a semi-supervised generative adversarial network that is sequence-based (similar to our sequence-based classifiers). Fairchild et al.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup> provided the prediction scores and SSGAN<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> made their implementation available. As both methods are designed specifically for predicting the origin of single nucleotide variants (SNVs), the external validation datasets were filtered accordingly.</p></sec></sec><sec id="Sec15" sec-type="supplementary-material"><title>Supplementary information</title><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41698_2025_921_MOESM1_ESM.pdf"><caption><p>Supplementary_Information</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary information</title><p>The online version contains supplementary material available at 10.1038/s41698-025-00921-w.</p></sec><ack><title>Acknowledgements</title><p>This study was funded by AstraZeneca.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>G.A.A., J.C.B., A.M., Z.L., and E.J. conceived the study. G.A.A. and E.J. designed the study. Algorithm development was carried out by G.A.A., M.H., and E.J. Data analysis was performed by G.A.A., M.H. and A.M. The manuscript was written by M.H., G.J.S., G.A.A., E.Y.C. and E.J. The work was supervised by E.J. All authors reviewed the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>Data from the pan-cancer TCGA dataset and all available studies from cBioPortal used to train METk are available at <ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov">https://portal.gdc.cancer.gov</ext-link> and cBioPortal.org. The data used to train the sequence-based classifiers are available at <ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/">https://www.cbioportal.org/</ext-link> under &#x0201c;msk_impact_2017&#x0201d; and &#x0201c;msk_ch_2020&#x0201d; for the tumor and blood datasets, respectively. Data used to train the cfDNA classifer can be obtained directly from the Razavi et al.<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. publication. External validation datasets can be obtained directly from the Chin et al.<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>., Chabon et al.<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>., Leal et al.<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>., and Zhang et al.<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. publications. Alternative ML models used for comparison in our analyses can be obtained from the Fairchild et al.<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. and SSGAN<sup><xref ref-type="bibr" rid="CR16">16</xref></sup> publications.</p></notes><notes notes-type="data-availability"><title>Code availability</title><p>The MetaCH framework is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/gaarangoa/MetaCH">https://github.com/gaarangoa/MetaCH</ext-link>. The METk package is available at <ext-link ext-link-type="uri" xlink:href="https://github.com/gaarangoa/METk">https://github.com/gaarangoa/METk</ext-link>.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par50">All authors are current or former employees of AstraZeneca with stock ownership, interests, and/or options in the company.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Diaz</surname><given-names>LA</given-names><suffix>Jr</suffix></name><name><surname>Bardelli</surname><given-names>A</given-names></name></person-group><article-title>Liquid biopsies: Genotyping circulating tumor DNA</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>579</fpage><lpage>586</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.45.2011</pub-id><pub-id pub-id-type="pmid">24449238</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Diaz, L. A. Jr &#x00026; Bardelli, A. Liquid biopsies: Genotyping circulating tumor DNA. <italic>J. Clin. Oncol.</italic><bold>32</bold>, 579&#x02013;586 (2014).<pub-id pub-id-type="pmid">24449238</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>MW</given-names></name><name><surname>Kircher</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>AJ</given-names></name><name><surname>Daza</surname><given-names>RM</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name></person-group><article-title>Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin</article-title><source>Cell</source><year>2016</year><volume>164</volume><fpage>57</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.11.050</pub-id><pub-id pub-id-type="pmid">26771485</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Snyder, M. W., Kircher, M., Hill, A. J., Daza, R. M. &#x00026; Shendure, J. Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. <italic>Cell</italic><bold>164</bold>, 57&#x02013;68 (2016).<pub-id pub-id-type="pmid">26771485</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA</article-title><source>Ann. Oncol.</source><year>2020</year><volume>31</volume><fpage>745</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2020.02.011</pub-id><pub-id pub-id-type="pmid">33506766</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Liu, M. C. et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. <italic>Ann. Oncol.</italic><bold>31</bold>, 745&#x02013;759 (2020).<pub-id pub-id-type="pmid">33506766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Alix-Panabi&#x000e8;res</surname><given-names>C</given-names></name><name><surname>Pantel</surname><given-names>K</given-names></name></person-group><article-title>Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy</article-title><source>Cancer Discov.</source><year>2016</year><volume>6</volume><fpage>479</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-1483</pub-id><pub-id pub-id-type="pmid">26969689</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Alix-Panabi&#x000e8;res, C. &#x00026; Pantel, K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. <italic>Cancer Discov.</italic><bold>6</bold>, 479&#x02013;491 (2016).<pub-id pub-id-type="pmid">26969689</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Steensma</surname><given-names>DP</given-names></name><etal/></person-group><article-title>Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes</article-title><source>Blood</source><year>2015</year><volume>126</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1182/blood-2015-03-631747</pub-id><pub-id pub-id-type="pmid">25931582</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. <italic>Blood</italic><bold>126</bold>, 9&#x02013;16 (2015).<pub-id pub-id-type="pmid">25931582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Razavi</surname><given-names>P</given-names></name><etal/></person-group><article-title>High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants</article-title><source>Nat. Med.</source><year>2019</year><volume>25</volume><fpage>1928</fpage><lpage>1937</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0652-7</pub-id><pub-id pub-id-type="pmid">31768066</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Razavi, P. et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. <italic>Nat. Med.</italic><bold>25</bold>, 1928&#x02013;1937 (2019).<pub-id pub-id-type="pmid">31768066</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>False-Positive Plasma Genotyping Due to Clonal Hematopoiesis</article-title><source>Clin. Cancer Res.</source><year>2018</year><volume>24</volume><fpage>4437</fpage><lpage>4443</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-0143</pub-id><pub-id pub-id-type="pmid">29567812</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Hu, Y. et al. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. <italic>Clin. Cancer Res.</italic><bold>24</bold>, 4437&#x02013;4443 (2018).<pub-id pub-id-type="pmid">29567812</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Chabon</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Integrating genomic features for non-invasive early lung cancer detection</article-title><source>Nature</source><year>2020</year><volume>580</volume><fpage>245</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2140-0</pub-id><pub-id pub-id-type="pmid">32269342</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Chabon, J. J. et al. Integrating genomic features for non-invasive early lung cancer detection. <italic>Nature</italic><bold>580</bold>, 245&#x02013;251 (2020).<pub-id pub-id-type="pmid">32269342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>K</given-names></name><etal/></person-group><article-title>Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference</article-title><source>JAMA Oncol.</source><year>2021</year><volume>7</volume><fpage>107</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2020.5161</pub-id><pub-id pub-id-type="pmid">33151258</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Jensen, K. et al. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference. <italic>JAMA Oncol.</italic><bold>7</bold>, 107&#x02013;110 (2021).<pub-id pub-id-type="pmid">33151258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Yaung, S. J. et al. Clonal Hematopoiesis in Late-Stage Non&#x02013;Small-Cell Lung Cancer and Its Impact on Targeted Panel Next-Generation Sequencing. <italic>JCO Precis Oncol.</italic><bold>4</bold>, 1271&#x02013;1279 (2020).</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Fairchild</surname><given-names>L</given-names></name><etal/></person-group><article-title>Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</article-title><source>Sci. Transl. Med.</source><year>2023</year><volume>15</volume><fpage>eabm8729</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abm8729</pub-id><pub-id pub-id-type="pmid">36989374</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Fairchild, L. et al. Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing. <italic>Sci. Transl. Med.</italic><bold>15</bold>, eabm8729 (2023).<pub-id pub-id-type="pmid">36989374</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Dang, D. K. &#x00026; Park, B. H. Circulating tumor DNA: current challenges for clinical utility. <italic>J. Clin. Invest.</italic><bold>132</bold>, 10.1172/jci154941 (2022).</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Si, H. et al. A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study. <italic>J. Clin. Cancer Res.</italic><bold>27</bold>, 1631&#x02013;1640 (2021).</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Adebayo, J. et al. Sanity checks for saliency maps. In: <italic>Advances in neural information processing systems</italic> 31 (NIPS, 2018).</mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>AL</given-names></name><name><surname>Tong</surname><given-names>RS</given-names></name><name><surname>Birmann</surname><given-names>BM</given-names></name><name><surname>Druley</surname><given-names>TE</given-names></name></person-group><article-title>Clonal hematopoiesis and risk of acute myeloid leukemia</article-title><source>Haematologica</source><year>2019</year><volume>104</volume><fpage>2410</fpage><pub-id pub-id-type="doi">10.3324/haematol.2018.215269</pub-id><pub-id pub-id-type="pmid">31004019</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Young, A. L., Tong, R. S., Birmann, B. M. &#x00026; Druley, T. E. Clonal hematopoiesis and risk of acute myeloid leukemia. <italic>Haematologica</italic><bold>104</bold>, 2410 (2019).<pub-id pub-id-type="pmid">31004019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Palizban</surname><given-names>F</given-names></name><name><surname>Sarbishegi</surname><given-names>M</given-names></name><name><surname>Kavousi</surname><given-names>K</given-names></name><name><surname>Mehrmohamadi</surname><given-names>M</given-names></name></person-group><article-title>Predicting somatic mutation origins in cell-free DNA by semi-supervised GAN models</article-title><source>Heliyon</source><year>2024</year><volume>10</volume><fpage>e39379</fpage><pub-id pub-id-type="doi">10.1016/j.heliyon.2024.e39379</pub-id><pub-id pub-id-type="pmid">39492904</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Palizban, F., Sarbishegi, M., Kavousi, K. &#x00026; Mehrmohamadi, M. Predicting somatic mutation origins in cell-free DNA by semi-supervised GAN models. <italic>Heliyon</italic><bold>10</bold>, e39379 (2024).<pub-id pub-id-type="pmid">39492904</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Sun, D. et al. Evaluation of a variant origin prediction (VOP) algorithm to distinguish clonal hematopoiesis (CH) variants from tumor-derived variants and to predict metastatic castrate resistant prostate cancer (mCRPC) clinical responses. <italic>J. Clin. Oncol.</italic><bold>43</bold>, 10.1200/JCO.2025.43.5_suppl.201 (2025).</mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Wu, L. et al. StarSpace: Embed All The Things, <ext-link ext-link-type="uri" xlink:href="https://ui.adsabs.harvard.edu/abs/2017arXiv170903856W">https://ui.adsabs.harvard.edu/abs/2017arXiv170903856W</ext-link> (2017).</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Bolton</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Cancer therapy shapes the fitness landscape of clonal hematopoiesis</article-title><source>Nat. Genet.</source><year>2020</year><volume>52</volume><fpage>1219</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1038/s41588-020-00710-0</pub-id><pub-id pub-id-type="pmid">33106634</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. <italic>Nat. Genet.</italic><bold>52</bold>, 1219&#x02013;1226 (2020).<pub-id pub-id-type="pmid">33106634</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Zehir</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>703</fpage><lpage>713</lpage><pub-id pub-id-type="doi">10.1038/nm.4333</pub-id><pub-id pub-id-type="pmid">28481359</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Zehir, A. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. <italic>Nat. Med.</italic><bold>23</bold>, 703&#x02013;713 (2017).<pub-id pub-id-type="pmid">28481359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>11</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-20162-8</pub-id><pub-id pub-id-type="pmid">33397889</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Zhang, Y. et al. Pan-cancer circulating tumor DNA detection in over 10,000 Chinese patients. <italic>Nat. Commun.</italic><bold>12</bold>, 11 (2021).<pub-id pub-id-type="pmid">33397889</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Chin</surname><given-names>YM</given-names></name><etal/></person-group><article-title>Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer</article-title><source>Cancer Sci.</source><year>2021</year><volume>112</volume><fpage>454</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1111/cas.14697</pub-id><pub-id pub-id-type="pmid">33075187</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Chin, Y. M. et al. Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. <italic>Cancer Sci.</italic><bold>112</bold>, 454&#x02013;464 (2021).<pub-id pub-id-type="pmid">33075187</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Leal</surname><given-names>A</given-names></name><etal/></person-group><article-title>White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>525</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-14310-3</pub-id><pub-id pub-id-type="pmid">31988276</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Leal, A. et al. White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. <italic>Nat. Commun.</italic><bold>11</bold>, 525 (2020).<pub-id pub-id-type="pmid">31988276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>LB</given-names></name><etal/></person-group><article-title>The repertoire of mutational signatures in human cancer</article-title><source>Nature</source><year>2020</year><volume>578</volume><fpage>94</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1943-3</pub-id><pub-id pub-id-type="pmid">32025018</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. <italic>Nature</italic><bold>578</bold>, 94&#x02013;101 (2020).<pub-id pub-id-type="pmid">32025018</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Niroula</surname><given-names>A</given-names></name><etal/></person-group><article-title>Distinction of lymphoid and myeloid clonal hematopoiesis</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>1921</fpage><lpage>1927</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01521-4</pub-id><pub-id pub-id-type="pmid">34663986</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Niroula, A. et al. Distinction of lymphoid and myeloid clonal hematopoiesis. <italic>Nat. Med.</italic><bold>27</bold>, 1921&#x02013;1927 (2021).<pub-id pub-id-type="pmid">34663986</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>JH</given-names></name><name><surname>Melloni</surname><given-names>GEM</given-names></name><name><surname>Gulhan</surname><given-names>DC</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name><name><surname>Haigis</surname><given-names>KM</given-names></name></person-group><article-title>The origins and genetic interactions of KRAS mutations are allele- and tissue-specific</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1808</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22125-z</pub-id><pub-id pub-id-type="pmid">33753749</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Cook, J. H., Melloni, G. E. M., Gulhan, D. C., Park, P. J. &#x00026; Haigis, K. M. The origins and genetic interactions of KRAS mutations are allele- and tissue-specific. <italic>Nat. Commun.</italic><bold>12</bold>, 1808 (2021).<pub-id pub-id-type="pmid">33753749</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Bick</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Inherited causes of clonal haematopoiesis in 97,691 whole genomes</article-title><source>Nature</source><year>2020</year><volume>586</volume><fpage>763</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2819-2</pub-id><pub-id pub-id-type="pmid">33057201</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Bick, A. G. et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. <italic>Nature</italic><bold>586</bold>, 763&#x02013;768 (2020).<pub-id pub-id-type="pmid">33057201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Cristiano</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genome-wide cell-free DNA fragmentation in patients with cancer</article-title><source>Nature</source><year>2019</year><volume>570</volume><fpage>385</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1272-6</pub-id><pub-id pub-id-type="pmid">31142840</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Cristiano, S. et al. Genome-wide cell-free DNA fragmentation in patients with cancer. <italic>Nature</italic><bold>570</bold>, 385&#x02013;389 (2019).<pub-id pub-id-type="pmid">31142840</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>SY</given-names></name><etal/></person-group><article-title>Sensitive tumour detection and classification using plasma cell-free DNA methylomes</article-title><source>Nature</source><year>2018</year><volume>563</volume><fpage>579</fpage><lpage>583</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0703-0</pub-id><pub-id pub-id-type="pmid">30429608</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Shen, S. Y. et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. <italic>Nature</italic><bold>563</bold>, 579&#x02013;583 (2018).<pub-id pub-id-type="pmid">30429608</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Stobbe</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Recurrent somatic mutations reveal new insights into consequences of mutagenic processes in cancer</article-title><source>PLoS Computational Biol.</source><year>2019</year><volume>15</volume><fpage>e1007496</fpage><pub-id pub-id-type="doi">10.1371/journal.pcbi.1007496</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Stobbe, M. D. et al. Recurrent somatic mutations reveal new insights into consequences of mutagenic processes in cancer. <italic>PLoS Computational Biol.</italic><bold>15</bold>, e1007496 (2019).</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name></person-group><article-title>Cancer mutational signatures representation by large-scale context embedding</article-title><source>Bioinformatics</source><year>2020</year><volume>36</volume><fpage>i309</fpage><lpage>i316</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btaa433</pub-id><pub-id pub-id-type="pmid">32657413</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Zhang, Y., Xiao, Y., Yang, M. &#x00026; Ma, J. Cancer mutational signatures representation by large-scale context embedding. <italic>Bioinformatics</italic><bold>36</bold>, i309&#x02013;i316 (2020).<pub-id pub-id-type="pmid">32657413</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gene2vec: distributed representation of genes based on co-expression</article-title><source>BMC Genomics</source><year>2019</year><volume>20</volume><fpage>7</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1186/s12864-018-5370-x</pub-id><pub-id pub-id-type="pmid">30611193</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Du, J. et al. Gene2vec: distributed representation of genes based on co-expression. <italic>BMC Genomics</italic><bold>20</bold>, 7&#x02013;15 (2019).<pub-id pub-id-type="pmid">30611193</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Ovens</surname><given-names>K</given-names></name><name><surname>Maleki</surname><given-names>F</given-names></name><name><surname>Eames</surname><given-names>BF</given-names></name><name><surname>McQuillan</surname><given-names>I</given-names></name></person-group><article-title>Juxtapose: a gene-embedding approach for comparing co-expression networks</article-title><source>BMC Bioinforma.</source><year>2021</year><volume>22</volume><fpage>1</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.1186/s12859-021-04055-1</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Ovens, K., Maleki, F., Eames, B. F. &#x00026; McQuillan, I. Juxtapose: a gene-embedding approach for comparing co-expression networks. <italic>BMC Bioinforma.</italic><bold>22</bold>, 1&#x02013;26 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Mou</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Tu</surname><given-names>Y</given-names></name></person-group><article-title>dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs</article-title><source>Genome Med.</source><year>2020</year><volume>12</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/s13073-020-00803-9</pub-id><pub-id pub-id-type="pmid">33261662</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Liu, X., Li, C., Mou, C., Dong, Y. &#x00026; Tu, Y. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. <italic>Genome Med.</italic><bold>12</bold>, 103 (2020).<pub-id pub-id-type="pmid">33261662</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Cingolani</surname><given-names>P</given-names></name><etal/></person-group><article-title>Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift</article-title><source>Front. Genet.</source><year>2012</year><volume>3</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.3389/fgene.2012.00035</pub-id><pub-id pub-id-type="pmid">22435069</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Cingolani, P. et al. Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift. <italic>Front. Genet.</italic><bold>3</bold>, 35 (2012).<pub-id pub-id-type="pmid">22435069</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Chakravarty, D. et al. OncoKB: A Precision Oncology Knowledge Base. <italic>JCO Precis. Oncol.</italic><bold>2017</bold>, 10.1200/PO.17.00011 (2017).</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Grinfeld</surname><given-names>J</given-names></name><etal/></person-group><article-title>Classification and Personalized Prognosis in Myeloproliferative Neoplasms</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>1416</fpage><lpage>1430</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1716614</pub-id><pub-id pub-id-type="pmid">30304655</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Grinfeld, J. et al. Classification and Personalized Prognosis in Myeloproliferative Neoplasms. <italic>N. Engl. J. Med.</italic><bold>379</bold>, 1416&#x02013;1430 (2018).<pub-id pub-id-type="pmid">30304655</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><etal/></person-group><article-title>Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts</article-title><source>N. Engl. J. Med.</source><year>2011</year><volume>365</volume><fpage>1384</fpage><lpage>1395</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1103283</pub-id><pub-id pub-id-type="pmid">21995386</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Papaemmanuil, E. et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. <italic>N. Engl. J. Med.</italic><bold>365</bold>, 1384&#x02013;1395 (2011).<pub-id pub-id-type="pmid">21995386</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><etal/></person-group><article-title>Genomic Classification and Prognosis in Acute Myeloid Leukemia</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>374</volume><fpage>2209</fpage><lpage>2221</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1516192</pub-id><pub-id pub-id-type="pmid">27276561</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Papaemmanuil, E. et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. <italic>N. Engl. J. Med.</italic><bold>374</bold>, 2209&#x02013;2221 (2016).<pub-id pub-id-type="pmid">27276561</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Wang, C., Wu, Q., Weimer, M. &#x00026; Zhu, E. FLAML: A Fast and Lightweight AutoML Library. In: <italic>Fourth Conference on Machine Learning and Systems</italic> (MLSys 2021).</mixed-citation></ref></ref-list></back></article>